Stock Analysis
BridgeBio Pharma, Inc. (BBIO) Stock Analysis
BridgeBio Pharma, Inc. (BBIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
BridgeBio Pharma, Inc. (BBIO) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 69/100. Value is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BBIO at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $78.30 |
| AIQ Score | 64/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $15.35B |
| P/E Ratio (TTM) | -25.76 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.42 |
| Revenue (Q3 FY2026) | $353.17M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.95 |
| Volume | 1.15M |
| 52-week range | $62.50-$93.42 |
| RSI 14 | 64.96 |
| 50-Day SMA | $69.98 |
| 200-Day SMA | $72.69 |
| Analyst Price Target | $111.17 |
| Next Earnings | Feb 23, 2027 |
BBIOBridgeBio Pharma, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum69
- Value55
- Quality66
- Risk resilience62
- Sentiment—
BBIO Stock Analysis Summary
BridgeBio Pharma, Inc. (BBIO) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 69/100. Value is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, BBIO has AIQ Score of 64/100 with Momentum base of 69/100 and fading Value at 55/100. Wait for component alignment before adding exposure.
Healthcare · 0.17% stock move · BBIO classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BBIO Bullish or Bearish Right Now?
BBIO currently has a neutral overall setup. Momentum is the strongest factor at 69/100, while Value is weakest at 55/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 66/100.
- - Momentum is constructive at 69/100.
- - Price is +11.89% above its 50-day SMA.
- - Analyst target implies +41.98% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 5).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
BBIO's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 5 neutral, and 5 sell votes. BBIO's 14-day RSI is 64.96, which places the stock in a constructive momentum range. BBIO's beta is 0.95, indicating market sensitivity broadly in line with the market.
What Changed in BBIO?
The largest recent change in BBIO is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the BBIO Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BBIO Decision Framework
Public evidence layers, setup checks, and risk context for BridgeBio Pharma, Inc..
BridgeBio Pharma, Inc. (BBIO) Stock Analysis
BridgeBio Pharma, Inc. has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 69/100. Beta is 0.95, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BBIO is in a Neutral AIQ regime with score 64/100. |
| Signal Conflict | The primary conflict is that momentum leads at 69/100 while value lags at 55/100. |
| Factor Evidence | Momentum 69/100 · Value 55/100 · Quality 66/100 · Risk 62/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 69/100.
Momentum is 69/100 and RSI (14) is 65.0.
BBIO is in a Neutral regime at 64/100.
Risk factor is 62/100 with beta 0.95 and annual volatility 44.14%.
Current conflict: momentum leads at 69/100 while value lags at 55/100.
BBIO Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BBIO Fundamentals
BBIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BBIO Technical Analysis
BBIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BBIO Stock Catalysts
Track BBIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BBIO Dividend Analysis
BBIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BBIO Financial Data
BBIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BBIO Risk Analysis
BBIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BBIO Stock News
BBIO stock news, market tone, recent headlines, and catalyst context.
BBIO vs Biotechnology Peers
Current peer cohort: BBIO · BCRX · BHVN · BLTE · CAI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BBIO Current stock | 64/100 | 55/100 | 69/100 | 62/100 | 0.55 | 44.14% | Current |
| BCRX BioCryst Pharmaceuticals, Inc. | 59/100 | 86/100 | 42/100 | 55/100 | 0.36 | 48.06% | BBIO vs BCRX |
| BHVN Biohaven Ltd. | 47/100 | — | 78/100 | 35/100 | 1 | 82.98% | BBIO vs BHVN |
| BLTE Belite Bio, Inc | 74/100 | — | 71/100 | 60/100 | 0.9 | 53.71% | BBIO vs BLTE |
| CAI Caris Life Sciences, Inc. | 70/100 | 68/100 | 85/100 | 36/100 | 0.22 | 69.82% | BBIO vs CAI |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for BBIO: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BBIO
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BBIO
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BBIO Stock FAQ
What is BBIO stock price today?
BridgeBio Pharma, Inc.'s current stock price is $78.30. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BBIO bullish or bearish right now?
BBIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BBIO's market cap?
BBIO's market cap is $15.35B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BBIO's current P/E ratio?
BBIO's current P/E ratio is -25.76 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BBIO's RSI?
BBIO's 14-day RSI is 64.96 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BBIO above its 50-day and 200-day moving averages?
BBIO is 11.89% from its 50-day SMA and 7.71% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BBIO's next earnings date?
BBIO's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BBIO pay a dividend?
BBIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.